Science

IQVIA Launches First Technology-Enabled COVID-19 Trial Matching Solution within the U.S. to Accelerate Treatment and Vaccine Development

Tuesday, April 7, 2020 - 12:00am

In response to this unprecedented crisis, IQVIA has created the first comprehensive online screener and trial matching tool for all U.S. COVID-19 trials, said Richard Staub, president, Research & Development Solutions at IQVIA.

Key Points: 
  • In response to this unprecedented crisis, IQVIA has created the first comprehensive online screener and trial matching tool for all U.S. COVID-19 trials, said Richard Staub, president, Research & Development Solutions at IQVIA.
  • IQVIA is focused on delivering industry-leading clinical development solutions to support and advance human health on behalf of our valued customers.
  • The IQVIA COVID-19 Trial Matching Tool is accessible at c19trials.com .
  • For more information about the IQVIA COVID-19 Trial Matching Tool, visit IQVIA.com.

BELLUS Health Announces Completion of Dosing in Phase 2 RELIEF Trial with BLU-5937 for the Treatment of Refractory Chronic Cough

Monday, April 6, 2020 - 10:00pm

The Company decided to close the trial early due to the impact of the COVID-19 pandemic on the RELIEF clinical trial activities.

Key Points: 
  • The Company decided to close the trial early due to the impact of the COVID-19 pandemic on the RELIEF clinical trial activities.
  • A total of 68 patients with refractory chronic cough were enrolled into the trial, with 52 completing treatment.
  • With 52 patients completing dosing, the RELIEF trial is the largest crossover study conducted in refractory chronic cough, providing the powering needed to evaluate efficacy and safety of BLU-5937, said Roberto Bellini, President and CEO of BELLUS Health.
  • BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders.

NanoString Provides COVID-19 Business Update and Announces Conference Call on Thursday May 7th, 2020

Monday, April 6, 2020 - 9:01pm

Our recently completed $230 million financing provides a strong balance sheet that will support the Company while we navigate this period of uncertainty.

Key Points: 
  • Our recently completed $230 million financing provides a strong balance sheet that will support the Company while we navigate this period of uncertainty.
  • Company management will host a conference call beginning at 4:30pm ET to discuss those results and provide a business update.
  • NanoString, NanoString Technologies, the NanoString logo, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.
  • You should read our unaudited consolidated financial statements for the three months ended March 31, 2020 once they become available.

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Monday, April 6, 2020 - 9:15pm

The options were granted as inducement equity awards outside of the Companys 2013 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4), and were made as an inducement material to the acceptance of employment with the Company by each of the new employees.

Key Points: 
  • The options were granted as inducement equity awards outside of the Companys 2013 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4), and were made as an inducement material to the acceptance of employment with the Company by each of the new employees.
  • The options are subject to the terms and conditions of stock option agreements covering the respective grants and the GlycoMimetics, Inc. Inducement Plan, which was adopted January 22, 2020 and provides for the granting of stock options to new employees.
  • The stock option awards have an exercise price equal to the closing price of the Companys common stock on April 1, 2020.
  • GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist.

Convalescent Plasma Collected in the Carolinas

Monday, April 6, 2020 - 8:19pm

The blood product, known as convalescent plasma , may have antibodies that can help those critically ill from COVID-19 to fight the virus.

Key Points: 
  • The blood product, known as convalescent plasma , may have antibodies that can help those critically ill from COVID-19 to fight the virus.
  • Blood donation is a wonderful way to give back and this convalescent plasma program is another way to help save lives in your community, said Delisa English, CEO and President of The Blood Connection.
  • If you have recovered from COVID-19, please consider donating plasma to help with the research that will help others to fight this virus.
  • If you are interested in donating convalescent plasma, please make an appointment at a center near you by calling The Blood Connection at (864)751-1168.

iBIO Commends Illinois the Life Sciences Community for its Impact through the iBIO COVID-19 PPE Response Fund

Monday, April 6, 2020 - 7:46pm

iBIO today announced that since the March 23rd launch of the iBIO COVID-19 PPE Response Fund , the Illinois life sciences community is making a significant impact in the fight against the coronavirus.

Key Points: 
  • iBIO today announced that since the March 23rd launch of the iBIO COVID-19 PPE Response Fund , the Illinois life sciences community is making a significant impact in the fight against the coronavirus.
  • Starting today and continuing each Monday, iBIO is posting weekly updates on the fund and its impact .
  • Astellas is the second Illinois-based life sciences company to offer significant support to the fund, following last weeks donation from Horizon Therapeutics .
  • The Illinois Biotechnology Innovation Organization (iBIO) is a life sciences industry association that represents the 85,000 life sciences employees at member companies, universities, service providers and venture firms.

Industrial Scientific Welcomes Saldy Antony as Vice President of Engineering

Monday, April 6, 2020 - 4:00pm

PITTSBURGH, April 6, 2020 /PRNewswire-PRWeb/ -- Industrial Scientific, the global leader in gas detection and connected safety, is pleased to announce that Saldy Antony has joined the company as Vice President of Engineering.

Key Points: 
  • PITTSBURGH, April 6, 2020 /PRNewswire-PRWeb/ -- Industrial Scientific, the global leader in gas detection and connected safety, is pleased to announce that Saldy Antony has joined the company as Vice President of Engineering.
  • Saldy will be responsible for leading the company's engineering team while also developing and executing the company's global technology strategy.
  • Saldy most recently served as vice president of engineering and product at Petcube, where he led a multi-national and multi-functional engineering team in the design and development of a complex IOT-enabled product.
  • "Across 23 years of engineering experience, Saldy has demonstrated his ability to drive tremendous improvement in technology and design for businesses," said Parker Burke, senior vice president and general manager of Industrial Scientific.

MedinCell Has Launched a COVID-19 Research Initiative Based on Its Experience to Formulate Long-Acting Injectable Ivermectin

Monday, April 6, 2020 - 6:41pm

Ivermectin has a long track record of use as a safe and effective drug to treat several parasitic diseases.

Key Points: 
  • Ivermectin has a long track record of use as a safe and effective drug to treat several parasitic diseases.
  • MedinCell has launched a few weeks ago a research initiative on a long-acting injectable formulation of Ivermectin and believes it could have a role to play in Covid-19 management.
  • In case of positive results, a BEPO technology based long-acting injectable Ivermectin offers a rapidly deployable and affordable solution for a global pandemic.
  • Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities.

Milken Institute Global Conference Rescheduled to October

Monday, April 6, 2020 - 6:30pm

The Milken Institute announced today that the 2020 Milken Institute Global Conference will be held October 12-15, 2020.

Key Points: 
  • The Milken Institute announced today that the 2020 Milken Institute Global Conference will be held October 12-15, 2020.
  • It had been scheduled to take place July 7-10 after the Milken Institute postponed the original dates of May 3-6, 2020.
  • These new dates were selected after evaluating public guidelines and in consultation with partners in government, medical research, and the private sector.
  • The global crisis demonstrates the need for individuals, organizations, and nations to bridge divides and work together to find solutions toand be better prepared foreconomic and health challenges like those we are facing now and in years to come, said Michael Klowden, CEO of the Milken Institute.

Chemical Insights Partners With Duke University to Research Air Pollution Impacts on Asthmatic Children

Monday, April 6, 2020 - 4:58pm

Chemical Insights , an Institute of Underwriters Laboratories, announced today the findings from its research collaboration with Duke University on the influence of outdoor and indoor air pollution on asthmatic children was published in JAMA Pediatrics, a journal of the American Medical Association.

Key Points: 
  • Chemical Insights , an Institute of Underwriters Laboratories, announced today the findings from its research collaboration with Duke University on the influence of outdoor and indoor air pollution on asthmatic children was published in JAMA Pediatrics, a journal of the American Medical Association.
  • Our research offers insights on solutions to combat the effects of those pollutants among sensitive groups.
  • A study group of children with mild to moderate asthma were given two air filters to use in their bedrooms.
  • Our results show that using an air purifier to reduce the exposure of lower airways to pollutants could help asthmatic children breathe easier.